Department of General, Visceral and Vascular Surgery, University Hospital Jena, Am Klinikum 1, 07740, Jena, Germany.
Comprehensive Cancer Center Central Germany (CCCG), 04103, Leipzig, Germany.
J Cancer Res Clin Oncol. 2024 Jul 13;150(7):349. doi: 10.1007/s00432-024-05884-2.
The biology of rare pancreatic tumours, which differs from that of ductal pancreatic cancer, requires increased attention. Although the majority of rare pancreatic tumours are benign, it is difficult to decide whether an invasive component exists without complete removal of the lesion, despite considerable progress in diagnosis. We are investigating a large cohort of patients with histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas.
Here we analyze long-term survival from patients, who underwent resection of histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas. At our department between Jan 1st, 1999, and Dec 31st, 2019. The median follow-up was 61 (range 0-168) month. All statistical analyses were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software.
46 patients (48%) were followed up for more than 5 years, 18 patients (19%) for more than 10 years. The 5-year and 10-year survival rates for rare non-invasive pancreatic tumours were 72% and 55% respectively. The proportion of rare tumour entities (non-ductal and non-neuroendocrine) increased continuously and statistically significantly (p = 0.004) from 4.2 to 12.3% in our clinic between 1999 and 2019. If there is no invasive growth yet, there is a varying risk of malignant degeneration in the course of the disease. Therefore, the indication for pancreatic resection is still the subject of discussion.
The long-term prognosis of rare epithelial pancreatic tumours after R0 resection-even if they are already malignant-is much better than that of ductal pancreatic cancer.
与导管性胰腺癌不同，罕见胰腺肿瘤的生物学特性需要引起更多关注。尽管大多数罕见胰腺肿瘤是良性的，但由于诊断方面取得了相当大的进展，即使完全切除病变，也很难确定是否存在侵袭性成分。我们正在对一组经组织学证实的胰腺上皮性非导管性非神经内分泌肿瘤患者进行研究。
在此，我们分析了在我们科室接受经组织学证实的胰腺上皮性非导管性非神经内分泌肿瘤切除术的患者的长期生存情况。时间范围为 1999 年 1 月 1 日至 2019 年 12 月 31 日。中位随访时间为 61（0-168）个月。所有统计分析均使用 SPSS 26.0（IBM，芝加哥，IL，USA 软件）进行。
46 例（48%）患者的随访时间超过 5 年，18 例（19%）患者的随访时间超过 10 年。罕见非侵袭性胰腺肿瘤的 5 年和 10 年生存率分别为 72%和 55%。在我们科室，1999 年至 2019 年间，罕见肿瘤实体（非导管性和非神经内分泌性）的比例持续且具有统计学意义地增加（p=0.004），从 4.2%增加到 12.3%。如果还没有侵袭性生长，那么在疾病的过程中，恶性转化的风险是不同的。因此，胰腺切除术的适应证仍然是讨论的主题。
即使已经是恶性的，R0 切除后罕见上皮性胰腺肿瘤的长期预后比导管性胰腺癌要好得多。
